PepGen Inc. (PEPG)
| Bid | 1.27 |
| Market Cap | 47.57M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.85 |
| PE Ratio (ttm) | -0.51 |
| Forward PE | -0.99 |
| Analyst | Buy |
| Ask | 1.65 |
| Volume | 198,813 |
| Avg. Volume (20D) | 2,914,681 |
| Open | 1.30 |
| Previous Close | 1.31 |
| Day's Range | 1.30 - 1.50 |
| 52-Week Range | 1.16 - 19.30 |
| Beta | 0.98 |
About PEPG
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1...
Analyst Forecast
According to 3 analyst ratings, the average rating for PEPG stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 724.74% from the latest price.
Stock Forecasts
19 hours ago · accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPGNEW YORK, NY / ACCESS Newswire / April 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc ("PepGen" or the "Company") (NASDAQ:PEPG). Such investors are advised to con...
2 months ago · accessnewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGNEW YORK CITY, NY / ACCESS Newswire / February 1, 2025 / SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG NEW YORK, February 1, 2025 (ACCESSWIRE) ...